#United States #New York #Cizzle Bio #Bill Behnke #AVBCC Summit

Insights from the 2025 AVBCC Summit

On October 22 to 24, 2025, New York City hosted the Association for Value-Based Cancer Care (AVBCC) Summit, a pivotal event focusing on the future of cancer diagnostics and care. At this summit, Bill Behnke, the founder and CEO of Cizzle Bio Inc., played a crucial role as moderator of a prominent panel dedicated to the theme of advancing cancer diagnostics in alignment with value-based healthcare frameworks.

The Panel and Its Significance

The session, titled Advancing Cancer Diagnostics to Commercialization: Bridging Innovation, Access, and Value, gathered esteemed experts from various sectors of oncology diagnostics, reimbursement systems, and digital health. The focus was to discuss how cutting-edge scientific innovations can be effectively converted into clinical practices that prioritize patient value, ultimately improving access and affordability.

“Innovation achieves its highest value when it reaches patients early and equitably,” remarked Bill Behnke at the beginning of the discussion. This statement underpinned the core objective of the panel: to elucidate the pathways through which new diagnostic technologies can reach patients and become integrated into standard care practices.

Key Takeaways from the Discussion

The dialogue highlighted Cizzle Bio’s commitment to revolutionizing early detection methods for lung and gastric cancers through advanced blood-based diagnostics driven by biomarker insights. Throughout the discussion, panelists navigated through the entire lifecycle of diagnostic innovation—starting from discovery and validation to commercialization and making them accessible to the general population. This holistic approach is vital for ensuring that innovative products not only fulfill clinical needs but are also practically implementable within the healthcare system.

Among the distinguished panelists were industry leaders such as Bobby Hill from Caris Life Sciences, Jennifer Hinkel of Sigla Sciences, and Ben Casavant from Tasso, Inc. Their collaboration resulted in a rich dialogue developed around the alignment of novel diagnostic innovations with payer expectations and health system priorities, including patient access goals.

The Future of Oncology Diagnostics

Behnke emphasized the necessity of integrating science, economics, and access to forge ahead in the realm of oncology diagnostics. He remarked, “Bringing together science, economics, and access is essential for the next era of oncology diagnostics.” This assertion reflects Cizzle Bio’s strategy of ensuring that innovations fulfill not just a scientific milestone but also a systemic standard for patient care.

The AVBCC Summit sees participation from a myriad of stakeholders within the life sciences, payer organizations, and clinical practice arenas, making it one of the premier forums focused on advancing value-based cancer care. This year, over 300 attendees and 90 sessions engaged in rich dialogue around emerging models integrating outcomes, access, and affordability across the oncology continuum.

Cizzle Bio's Commitment to Innovation

Cizzle Bio is steadfastly on a mission to bridge the gap between diagnostic innovation and practical implementation. This commitment involves the advancement of blood-based biomarker tests designed to detect cancers, including lung and gastric cancers, in their earliest stages, which significantly increases treatment effectiveness.

Currently, Cizzle Bio is commercializing its proprietary tests, the CIZ1B for lung cancer and the DEX-G2 for gastric cancer, which are expected to become available shortly to licensed healthcare providers in the United States. Both tests are pivotal in the company’s strategy of early cancer detection that prioritizes patient empowerment and improved healthcare outcomes through technological innovation.

About Cizzle Bio

Cizzle Bio is based in Texas and aims to transform cancer diagnostics through pioneering biomarker-based blood tests. Their primary focus lies in the early detection of lung and gastric cancers, aspiring to enhance patient outcomes through innovative solutions that carry compassion and efficacy at their core. The company holds exclusive licensing for its groundbreaking tests across various regions, including the United States, Canada, and the Caribbean, and is making strides in clinical environments for practical application.

As conversations about integrating diagnostics innovation and value continue, organizations like Cizzle Bio play an essential role in shaping the future landscape of cancer care and detection. With a robust commitment to patient-centered care, the company's endeavors signify a transformative period in the oncology field.